AbbVie (NYSE:ABBV) Announces Earnings Results, Beats Expectations By $0.09 EPS

AbbVie (NYSE:ABBV) released its quarterly earnings data on Friday. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09, Zacks reports. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the firm earned $3.00 earnings per share. AbbVie updated its Q4 2025 guidance to 3.320-3.360 EPS.

AbbVie Trading Down 4.4%

AbbVie stock opened at $218.14 on Friday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The business’s 50-day simple moving average is $222.42 and its 200-day simple moving average is $200.94. The firm has a market capitalization of $385.35 billion, a PE ratio of 103.87, a PEG ratio of 1.42 and a beta of 0.51. AbbVie has a 52 week low of $163.81 and a 52 week high of $244.81.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s dividend payout ratio is presently 312.38%.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of research reports. Bank of America lifted their price objective on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Citigroup reaffirmed a “neutral” rating on shares of AbbVie in a research report on Monday, October 13th. BMO Capital Markets boosted their price target on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research report on Friday, September 12th. Daiwa America raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 7th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $250.00 price target (up previously from $236.00) on shares of AbbVie in a research report on Friday, October 17th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $234.80.

Insider Transactions at AbbVie

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the transaction, the executive vice president owned 58,247 shares in the company, valued at $11,562,611.97. The trade was a 18.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.25% of the company’s stock.

Hedge Funds Weigh In On AbbVie

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rakuten Securities Inc. increased its stake in AbbVie by 26.5% during the second quarter. Rakuten Securities Inc. now owns 368 shares of the company’s stock valued at $68,000 after acquiring an additional 77 shares during the period. Binnacle Investments Inc increased its stake in AbbVie by 33.2% during the second quarter. Binnacle Investments Inc now owns 493 shares of the company’s stock valued at $92,000 after acquiring an additional 123 shares during the period. Darwin Wealth Management LLC bought a new position in AbbVie during the second quarter valued at about $277,000. Redwood Financial Network Corp increased its stake in AbbVie by 10.8% during the second quarter. Redwood Financial Network Corp now owns 1,649 shares of the company’s stock valued at $306,000 after acquiring an additional 161 shares during the period. Finally, WFA of San Diego LLC bought a new position in AbbVie during the second quarter valued at about $333,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.